Close menu




June 15th, 2021 | 13:15 CEST

CureVac, Cardiol Therapeutics, Bayer: Healthcare for the portfolio

  • Biotechnology
Photo credits: pixabay.com

Biotechnology and pharmacology offer us great opportunities. For decades, the world has suffered from a few serious diseases: cancer, cardiovascular disease, Alzheimer's, diabetes and others. Where previously only symptoms were treated, there is now the prospect of a cure thanks to new processes. Even if it still takes a little time to reach market maturity: the innovative companies are already on the market, investors can invest.

time to read: 3 minutes | Author: Nico Popp
ISIN: NL0015436031 , CA14161Y2006 , DE000BAY0017

Table of contents:


    CureVac: Will this share become a value opportunity?

    The share of CureVac has come under the wheels in recent days. The reason: the german mRNA specialist and prospective vaccine manufacturer fell further behind the competition in the race for effective vaccines against Covid-19. Most recently, the process was delayed even further. In the market, this caused a sell-off. In the meantime, CureVac is valued at about the same level as Novavax. However, the latter Company does not rely on innovative mRNA technology but protein-based nanoparticles. This process has far fewer potential applications than mRNA technology.

    CureVac is a leader in mRNA and has many years of experience. It could be helpful when it comes to vaccines against other diseases, such as cancer. Currently, the share has fallen out of favor with the market. However, this does not necessarily mean anything in the long term. Today, the share price is burdened by the fact that CureVac will continue to depend on alliances with pharmaceutical giants or the capital market when investing large sums, while the ruble is already rolling at its competitor BioNTech thanks to vaccine sales. In the short term, this may put further pressure on the CureVac share. However, as soon as the sell-off comes to an end, CureVac will become interesting again - the mRNA technology and the Swabians' expertise gathered in this field are too promising.

    Cardiol Therapeutics: Good for the heart, soon on the Nasdaq?

    While CureVac's stock is weakening right now, Cardiol Therapeutics has already bottomed out. Cardiol Therapeutics focuses on the active ingredient cannabidiol, which is found in the cannabis plant. However, the team around CEO David Elsley does not believe in being a cannabis company. Cardiol Therapeutics is a biotechnology company that uses cannabidiol (CBD) to treat potentially fatal inflammatory processes in the heart. The approach stems from an article in the Journal of the American College of Cardiology that showed CBD could reverse fibrosis in the heart.

    At the end of April, Cardiol Therapeutics announced the start of a Phase II / III outcome study with high-risk patients admitted to hospital with Covid-19. The aim is to test the effect of the unique CBD formula on high-risk patients. If the pandemic comes to an end, the study results can also be used for a regular approval process to treat inflammatory heart disease. Cardiol Therapeutics has already achieved promising interim results and is currently preparing for a listing on Nasdaq. The Company expects this to bring new attention from investors. Currently, the Company, which is targeting one of the most serious diseases of our time, is valued at only about EUR 93 million. Comparable companies on the Nasdaq could make significant gains after their listing and reach values in the billions. (Read also the interview with Cardiol CEO David Elsley).

    Bayer: A dividend stock without a lot of frills

    While companies like CureVac or Cardiol Therapeutics are primarily concerned with growth, Bayer is considered a solid pharmaceutical and chemical company. The pharmaceuticals division accounts for just over 40% of Bayer's sales; only the seed business is more important. Last year, Bayer benefited from its solid market position despite the pandemic. Although the performance of agricultural products was poorer, this area, in particular, is once again in demand because of rising prices. Nevertheless, the stock is moving sideways at best. In three months, the stock has gained just 2%. Over a year, the stock has lost 16.6%. Bayer may not have much growth potential, but it is active worldwide and offers a healthy dividend of more than 5%.

    Bayer, CureVac and Cardiol Therapeutics show that there is good money to be made in drugs and related products. While Bayer is anything but dynamic as a top dog, the Company certainly offers a home to conservative dividend hunters. Those looking for short-term growth opportunities, however, are better off with Cardiol Therapeutics. The fight against heart disease is gaining in importance, especially in connection with Covid-19. In addition, there is the planned Nasdaq listing. CureVac also has long-term potential, but there is no catalyst to help the share price get off the ground in the short term.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

    Read